Esperion Therapeutics, Inc.
ESPR is undervalued
NASDAQ · Healthcare
FAIR PRICE
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
$3.18
MARKET PRICE
$4.24
FAIR PRICE
$1.06
MARGIN
COMMUNITY BUY ZONE
UNLOCKS AT 10
Where does the market buy ESPR?
No one has priced ESPR yet — be the first. Every investor sets the maximum price they'd still buy at; together that maps the community buy zone.
COMMUNITY MEDIAN
▓▓▓▓▓
BUYERS AT TODAY'S PRICE
▓▓ %
0/10 INVESTORS · 10 MORE TO UNLOCK
METRICS
NOW AVAILABLE
Get notified when ESPR's fair price changes
Push notifications when ESPR's valuation shifts. Available on iOS and Android.
FPI RATING
Consistent growth trajectory and high-quality fundamentals, but expensive valuation relative to fundamentals and elevated debt levels.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$3.39
Fair price × 0.80
DISTANCE
6.7%
Price to entry level
At the current price of $3.18, ESPR trades 6.7% below the conservative entry level of $3.39. The stock is currently priced below the 20% margin of safety threshold, indicating a potential value opportunity based on the model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
SYNCING FEED ▌
P/E RATIO HISTORY
SYNCING FEED ▌
METHODOLOGY
How we calculate ESPR's fair price
Esperion Therapeutics, Inc.'s fair price of $4.24 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $3.18, ESPR trades 33.3% below its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting ESPR's risk profile.
RELATIVE · 30%
Comparing ESPR's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for ESPR, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate ESPR's fair value with your own inputs.
ESPR DCF Calculator
Pre-filled with ESPR's real free cash flow and share count — set your own growth and discount rate to calculate intrinsic value.
Graham Number
Enter ESPR's EPS and book value to see the maximum price Benjamin Graham would pay for this stock.
P/E Ratio Calculator
Check how much investors pay per dollar of ESPR's earnings and compare it against sector benchmarks.
EV/EBITDA Calculator
Compare ESPR against peers on a debt-adjusted basis using enterprise value and EBITDA.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for ESPR.
Explore on BuliosFAQ
What is the fair price of ESPR?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Esperion Therapeutics, Inc. is $4.24. At the current market price of $3.18, ESPR trades 33.3% below its calculated fair value.
Is ESPR overvalued or undervalued?+
Esperion Therapeutics, Inc. is currently undervalued based on our valuation model. The stock trades at $3.18, which is 33.3% below the fair price of $4.24.
What is the margin of safety for ESPR?+
With a 20% margin of safety applied to the fair price of $4.24, the conservative entry level for ESPR is $3.39. At the current market price of $3.18, the stock trades 6.7% below this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is ESPR's fair price updated?+
We update fair price calculations for ESPR daily after market close. The current fair price of $4.24 incorporates the latest market data and sector multiples.
What factors affect ESPR's fair price calculation?+
ESPR's fair price of $4.24 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)..
Is ESPR a good buy right now?+
At $3.18, ESPR trades 33.3% below our fair value estimate of $4.24. The stock is currently undervalued. Fair Price Index provides valuation data — always do your own research before investing.
Does ESPR pay dividends?+
ESPR does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.